“We are excited to evaluate the efficacy and safety of FSD202 in a Phase 2 trial for the treatment of nociplastic pain associated with idiopathic MCAS. These patients often have a significantly ...

Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome. Quantum BioPharma .

Chronic widespread musculoskeletal nociplastic pain, a type of chronic pain characterized by altered pain perception that is not directly due to tissue injury, is associated with MCAS. The cause ...

bWalter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD, USA ...

that it has received approval by the human ethics review committee (HREC) in Australia for its trial entitled "A Randomized, Double-Blind Placebo Controlled Parallel Group Decentralized Trial to ...

iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients. iNGENū CRO . Mon, Jun 2, 2025, 1:47 PM 3 min read.

Morningstar brands and products Company Portfolio ...

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to ...

iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients Provided by GlobeNewswire Jun 2, 2025, 5:47:30 PM ...

“We are excited to evaluate the efficacy and safety of FSD202 in a Phase 2 trial for the treatment of nociplastic pain associated with idiopathic MCAS.